Expressions of coordinated stimulating molecular programmed death 1 and its ligand 1 in brain glioma and their clinical significances
10.3760/cma.j.issn.1006-9801.2020.01.007
- VernacularTitle: 协同刺激分子程序性死亡受体1及其配体1在脑胶质瘤中的表达及其临床意义
- Author:
Jianhong LI
1
;
Lili MA
2
;
Lina ZHANG
3
Author Information
1. Department of Neurosurgery, Heji Hospital Affiliated to Changzhi Medical College, Changzhi 046011, China
2. Department of Pathology, Heping Hospital Affiliated to Changzhi Medical College, Changzhi 046000, China
3. Department of Immunology, Changzhi Medical College, Changzhi 046000, China
- Publication Type:Journal Article
- Keywords:
Brain neoplasms;
Glioma;
Programmed death 1;
Programmed death ligand 1;
Immunohistochemistry
- From:
Cancer Research and Clinic
2020;32(1):32-35
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the expressions of coordinated stimulating molecular programmed death 1(PD-1) and programmed death ligand 1 (PD-L1) in human glioma and their clinical significances.
Methods:A total of 70 postoperative paraffin specimens of brain glioma and 35 normal brain tissues in Heji Hospital Affiliated to Changzhi Medical College from January 2013 to December 2017 were collected. The expressions of PD-1 and PD-L1 in 70 glioma tissues and 35 normal brain tissues were detected by immunohistochemical SP method. The relationship between the expressions of PD-1 and PD-L1 and their correlation with the clinicopathological features were analyzed.
Results:The positive expression rates of PD-1 and PD-L1 in glioma tissues were 69% (48/70) and 62% (43/70), respectively, which were higher than those in normal brain tissues [29% (10/35), 31% (11/35)], the differences were statistically significant (χ2 values were 15.099 and 8.407, both P < 0.05). The positive expression rates of PD-1 and PD-L 1 in high-grade glioma were 81% (30/37) and 73% (27/37), respectively, which were higher than those in low-grade glioma [55% (18/33) and 49% (16/33)], the differences were statistically significant (χ 2 values were 5.699 and 4.415, both P < 0.05). There was no significant difference in the positive expression rates of PD-1 and PD-L1 among patients with different sex, age and maximum tumor diameter (all P > 0.05). There was a positive correlation between the expressions of PD-1 and PD-L1 proteins in glioma tissues (r= 0.372, P= 0.002).
Conclusions:The PD-1 and PD-L1 may become new biological indicators for evaluating the occurrence and development of glioma.
